Nasdaq · Biotech stocks database
BNTX (BioNTech SE) stock: $96.06, $24.13B market cap, $9.02B cash, $15.11B EV, $24.35B fully diluted market cap. Next expected readout: Oct-26. Lead program: BNT162b2 (COVID-19 Vaccines), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $9,018.6M |
|---|---|
| Debt | $0.0M |
| Net cash | $9,018.6M |
| Enterprise value | $15,112.1M |
| Basic shares | 251.2M shares |
| Fully diluted shares | 253.5M shares |
| Fully diluted market cap | $24,352.7M |
| Cash per share | $35.90 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading BNTX daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Sep 29 - Nov 10 | BNT314 | Phase 1 | Advanced Malignant Solid Tumor | — |
| Nov 12 - Dec 24 | BNT163 | Phase 1 | Genital Herpes Simplex Type 2 | — |
| Dec 13, 2026 - Jan 24, 2027 | BNT351 | Phase 1 | HIV -1 Infection | — |
| Jan 12 - Feb 23 | YL202 | Phase 1 | Non Small Cell Lung Cancer; Breast Cancer | — |
| Jun 1 - Jul 13 | BNT162b2 | Phase 3 | COVID-19 Vaccines | — |
| Jun 12 - Jul 24 | PM8002 | Phase 2 | CRC (Colorectal Cancer) | — |
| Jul 13 - Aug 24 | BNT327 Dose Level 1 (DL1) | Phase 2 | Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer | — |
| Jul 13 - Aug 24 | BNT166a | Phase 2 | Mpox (Monkeypox); Smallpox; Orthopoxvirus Infection | — |
| Sep 12 - Oct 24 | Pertuzumab Injection | Phase 2 | HER2-positive Advanced Solid Tumor | — |
| Sep 12 - Oct 24 | GEN1042 | Phase 1 | Malignant Solid Tumor | — |
| Sep 24 - Nov 5 | BNT327 | Phase 2 | Advanced Solid Tumor | — |
| Dec 13, 2027 - Jan 24, 2028 | BNT3212 | Phase 2 | Advanced Solid Tumor | — |
| Jan 12 - Feb 23 | Pumitamig | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | — |
| Jan 12 - Feb 23 | DB-1311 | Phase 2 | Advanced Solid Tumors | — |
| Feb 12 - Mar 25 | Pumitamig | Phase 2 | Recurrent Glioblastoma | — |
| Mar 8 - Apr 19 | BNT116 | Phase 2 | Advanced Non-Small Cell Lung Cancer | — |
| Mar 14 - Apr 25 | BNT168 | Phase 1 | HIV -1 Infection | — |
| Apr 12 - May 24 | Doxorubicin | Phase 3 | Endometrial Cancer | — |
| Apr 12 - May 24 | BNT326 | Phase 2 | Advanced Solid Tumor | — |
| Sep 12 - Oct 24 | BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer | — |
| Sep 12 - Oct 24 | BNT327 Dose Level 1 (DL1) | Phase 2 | Locally Advanced Breast Cancer; Triple Negative Breast Cancer; Metastatic Triple Negative Breast Cancers | — |
| Sep 12 - Oct 24 | CLDN6 CAR-T | Phase 1 | Solid Tumor | — |
| Oct 13 - Nov 24 | BNT324 | Phase 2 | Advanced Lung Cancer | — |
| Nov 12 - Dec 24 | Pumitamig | Phase 2 | Non-small Cell Lung Cancer | — |
| Dec 13, 2028 - Jan 24, 2029 | BNT326 | Phase 2 | Non-small Cell Lung Cancer | — |
| Jan 12 - Feb 23 | Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | — |
| Feb 12 - Mar 26 | Pumitamig | Phase 3 | Non-small Cell Lung Cancer | — |
| Sep 12 - Oct 24 | BNT323 | Phase 2 | Locally Advanced Breast Cancer; Unresectable Breast Carcinoma; Metastatic Breast Cancer | — |
| Jan 12 - Feb 23 | Pumitamig | Phase 3 | Breast Neoplasms | — |
| Mar 15 - Apr 26 | BNT116 | Phase 1 | Non-Small Cell Lung Cancer | — |
| Jun 12 - Jul 24 | BNT329 | Phase 2 | Advanced Solid Cancers | — |
| Aug 11 - Sep 22 | BNT327 | Phase 2 | Solid Tumors | — |
| Nov 12 - Dec 24 | BNT3214 | Phase 2 | Advanced Solid Tumor Cancer | — |
| Jan 12 - Feb 23 | BNT314 | Phase 2 | Metastatic Colorectal Cancer | — |
| Feb 12 - Mar 26 | Autogene cevumeran | Phase 2 | Adenocarcinoma, Pancreatic Ductal | — |
| Mar 15 - Apr 26 | BNT324 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | — |
| May 13 - Jun 24 | BNT317 DL1 | Phase 2 | Advanced Solid Tumor | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.